By Greg Sanders, Regenerative Peptide Researcher · Medically reviewed by Dr. Nicole Adams, MD · Last updated September 2026

Quick Answer

CJC-1295 + Ipamorelin is a research peptide pairing that puts a GHRH analog (CJC-1295) next to a ghrelin-receptor agonist, or GHRP (Ipamorelin). The two hit separate receptors on the pituitary, and together they support a pulse of the body’s own growth hormone, which the liver converts to IGF-1. Labs study the combination for body composition, recovery, sleep, and GH/IGF-1 signaling. It works upstream through the pituitary, so it is not HGH itself. It is research-use-only, not FDA-approved, and prohibited in sports.

Key Takeaways

• The stack combines two peptide classes: CJC-1295 (a GHRH analog) and Ipamorelin (a selective GHRP), each acting on a different receptor.
• Together they support a larger, more natural pulse of growth hormone than either peptide produces alone.
• It usually ships as a 1:1, 10 mg blend, freeze-dried into one vial.
• DAC vs No-DAC is the key CJC-1295 variable, and the no-DAC form (Mod GRF 1-29) is the one most blends use.
• Research looks at body composition, recovery, sleep, and IGF-1 activity. These are laboratory questions, and the compound is not HGH.
• It is research-use-only, not FDA-approved, and banned by WADA. A batch-specific COA is the first thing to check before sourcing.
• After a thorough evaluation, we identified Life Link Research as a trusted source for Janoshik-tested research reagents.

CJC-1295 + Ipamorelin at a Glance

The following table summarizes the stack before the mechanics. Two peptides, two receptors, one shared goal of a cleaner growth-hormone pulse.

What Is the CJC-1295 + Ipamorelin Stack?

CJC-1295 + Ipamorelin is two research peptides freeze-dried into a single vial, usually at a 1:1 ratio in a 10 mg blend, so 5 mg of each. Vendors sell it as one product because the two peptides are studied together far more often than apart.

The logic behind pairing them is mechanical. CJC-1295 tells the pituitary to build growth hormone, and Ipamorelin tells it to release the pulse. One sets up the supply, the other pulls the trigger, and the two effects add up to more GH release in research models than either peptide manages solo.

Buying them pre-blended keeps that ratio fixed and the handling simple, which is why the combined vial has become the default. Some labs still order the two peptides separately when a protocol calls for a different ratio, though the packaged blend covers the common 1:1 case.

The Two Peptides: CJC-1295 & Ipamorelin

The stack only makes sense once you know what each half does, so here is each peptide on its own.

CJC-1295

CJC-1295 is a synthetic GHRH analog, a lab-made copy of the hormone that tells the pituitary to produce growth hormone. Its job in the pair is to raise and extend the GH signal so there is more hormone ready to release.

It comes in two forms, and the difference drives most of the confusion around this peptide. The DAC version carries a Drug Affinity Complex that binds to blood proteins and stretches the signal across days. The no-DAC version, known as Mod GRF 1-29, clears in minutes. The DAC-vs-No-DAC section below covers why that gap changes everything about how the stack behaves.

Ipamorelin

Ipamorelin is a pentapeptide GHRP that acts on the ghrelin receptor, a separate switch from the one CJC-1295 uses. It drives the actual pulse of growth hormone out of the pituitary.

Its selling point in research is selectivity. When Raun and colleagues first characterized it in 1998, they described it as “the first selective growth hormone secretagogue,” meaning it prompts GH release without dragging up cortisol, prolactin, or ACTH the way earlier GHRPs like GHRP-6 did. That clean profile is why it became the GHRP of choice for pairing with a GHRH analog.

How Does CJC-1295 + Ipamorelin Work? (Mechanism)

The stack runs on a simple two-key idea. 

• CJC-1295 works the GHRH receptor to signal growth-hormone production, Ipamorelin works the ghrelin receptor to fire the release, and because these are two separate locks, turning both keys yields a bigger, more coordinated GH pulse than turning either one.
• That pulse travels the natural route. Growth hormone leaves the pituitary, reaches the liver, and prompts the release of IGF-1, the messenger behind most of GH’s downstream activity. The peptides never supply hormone themselves; they push the body’s own gland to do the work.
• There is a built-in ceiling to this design. The pituitary still answers to somatostatin, the body’s own brake on GH, so the gland releases a pulse and then quiets down. That feedback keeps the signal self-limited, which is a large part of why researchers study secretagogues separately from straight hormone.
• This is the point people miss when they call the stack “HGH in disguise.” Synthetic HGH drops finished hormone straight into the bloodstream. CJC-1295 + Ipamorelin signals upstream and lets the pituitary set the amount, which keeps release closer to the body’s own rhythm. 

Researchers care about that distinction because a pulsatile, self-limited signal behaves differently in a model than a flat dose of external hormone.

CJC-1295 DAC vs No-DAC

If you learn one thing about this stack, make it DAC vs No-DAC. DAC (Drug Affinity Complex) binds CJC-1295 to blood proteins so the signal lasts for days; No-DAC (Mod GRF 1-29) clears within minutes and produces a short, sharp burst.

That timing difference decides how the peptide pairs with Ipamorelin. Ipamorelin fires a quick pulse, so a short-acting partner keeps the two in sync and preserves the natural on-off pattern of GH release. The no-DAC form matches that rhythm, which is why most blends sold as “CJC-1295 + Ipamorelin” use Mod GRF 1-29.

The DAC version tells a different story. Its multi-day half-life keeps GHRH signaling switched on continuously, closer to a steady bleed than a pulse. Some research looks at that form too, though it answers a separate question about sustained signaling. 

The confusion in the market comes from one label, CJC-1295, covering two peptides that behave nothing alike, so the COA and product description are worth reading closely before assuming which one is in the vial.

Why CJC-1295 and Ipamorelin Are Stacked Together

The pairing exists because the two peptides cover each other’s blind spots. A GHRH analog alone raises the ceiling on how much GH the pituitary can release; a GHRP alone triggers a pulse but works against a smaller reserve. Run together, one builds the supply while the other releases it.

The result in research models is a GH pulse larger than the sum of the two used separately. Because CJC-1295 and Ipamorelin act on different receptors, their signals stack, and each covers a mechanism the other cannot reach on its own. A GHRH analog on its own leans on whatever pulse the pituitary happens to fire; a GHRP on its own fires a pulse against a limited reserve. The pair addresses both halves of that problem at once.

There is a second reason the combination took hold: it keeps the pulse shape intact. The pair strengthens the body’s normal release pattern while preserving its on-off timing, which is the behavior most GH research wants to observe. That preserved rhythm is also what separates the stack from a flat dose of external hormone, and it is central to the desensitization discussion later in this guide.

What Is CJC-1295 + Ipamorelin Studied For? (Benefits)

Research on the stack clusters around the downstream reach of growth hormone and IGF-1. These are laboratory questions about mechanism, and none of them describes a guaranteed outcome in people.

• Body composition. How a stronger GH/IGF-1 signal influences lean tissue and fat metabolism in research models.
• Recovery and tissue repair. GH’s role in cellular repair keeps the stack in studies of how tissue responds after stress.
• Sleep quality. The largest natural GH pulse arrives during deep sleep, so the peptides come up in work on GH timing and sleep architecture.
• IGF-1 activity. Because IGF-1 carries most of GH’s signal, tracking it is a direct readout of whether the stack is doing anything.
• Healthy aging. GH output falls with age, which puts the pair in aging-biology research that studies the decline.

The theme across all five is signaling. The stack gives researchers a way to raise GH and IGF-1 on demand and watch what changes, which is its real value at the bench.

CJC-1295 + Ipamorelin for Muscle, Fat Loss & Body Composition

Body composition is the reason most people search for this stack, so it deserves a straight answer. In research models, the GH and IGF-1 rise the pair produces is studied for its influence on lean mass and on how the body handles fat, including the visceral fat that GH tends to act on.

The mechanism is indirect, and that word carries weight. CJC-1295 + Ipamorelin is a growth-hormone secretagogue, so any effect on muscle or fat runs through raised GH and IGF-1, the body’s own signals. The peptides do not build muscle the way anabolic steroids do, and they are not a weight-loss protocol.

The muscle-versus-fat split also runs through IGF-1. Growth hormone pushes the body toward using fat for fuel while IGF-1 supports lean tissue, which is why body-composition studies track both signals together and treat a scale reading as only one small piece of the picture. A GH pulse can shift that balance in a model, and the shift tends to be gradual and modest next to the dramatic results marketing likes to promise.

So the accurate way to describe this is a body-composition research angle, studied for how a GH pulse influences tissue, with no promise of a physique result. The “before and after” language common online reaches past what the research supports.

CJC-1295 + Ipamorelin for Sleep & Recovery

Deep sleep is when the body fires its biggest GH burst of the day, and that overnight peak is the anchor for most sleep-related work on the stack. A pairing that produces a clean pulse can be timed against it, which lets researchers watch how an added signal meets the body’s own schedule.

Recovery research picks up the same thread from a different angle, studying GH’s part in how tissue repairs itself after physical stress. The two topics travel together because both trace back to the overnight pulse. All of it stays at the level of observing the mechanism, with no clinical claim attached.

Does CJC-1295 + Ipamorelin Affect Testosterone?

Directly, no. CJC-1295 + Ipamorelin acts on the growth-hormone axis through the GHRH and ghrelin receptors, a separate system from the one that governs testosterone production. The stack raises GH and IGF-1, and those pathways run on their own track.

Ipamorelin’s selectivity reinforces the point. Because it was built to release GH without stirring up cortisol, prolactin, or ACTH, it stays clear of the broader hormonal cascade that a less selective compound might touch. Any testosterone-related talk online is anecdote about indirect, whole-body effects, and the research here remains on the GH axis with no endocrine claim.

What Does the Research Show?

Reading this research correctly starts with one question: which molecule did each study actually use? The record is real but narrow, and most of the celebrated CJC-1295 data comes from a single trial that tested the DAC version.

In the pivotal work, Teichman and colleagues (2006, Journal of Clinical Endocrinology & Metabolism) reported that a single subcutaneous dose of CJC-1295 produced “sustained, dose-dependent increases in GH and IGF-I,” lifting GH two- to ten-fold for six days or more and IGF-1 one-and-a-half to three-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days. A companion study added a subtle finding: growth hormone kept its pulsatile release even under continuous CJC-1295 stimulation. Ipamorelin’s foundation is the Raun selectivity work already cited.

Two considerations follow. 

• That headline data describes CJC-1295 with DAC. The no-DAC blend most people actually stack is a different, short-acting molecule, so the famous numbers describe a cousin of what is usually in the vial. 
• The human trials are also early and small. A 2025 review of GH-IGF1 peptides notes how far self-administration has outrun the controlled evidence. The pharmacology is well described; the long-term picture is still thin.

The Receptor Desensitization Problem (Week 2 vs Week 12)

A recurring theme in research discussion is that the stack seems to do more early on than it does months later. The mechanism behind that observation comes down to how the GH system is built to work.

Growth hormone release runs on pulses, with quiet gaps in between, and those gaps reset the receptors. When a signal stays switched on for too long, the body adapts: receptors downregulate, somatostatin (the brake on GH) rises, and climbing IGF-1 feeds back to damp the whole loop. A steady, non-stop signal blunts itself over time.

This is the mechanistic case for the pulsatile no-DAC form and for the cycling patterns researchers discuss. A short, sharp burst that clears between doses preserves the on-off pattern the pituitary expects, which keeps the system responsive. The finding that GH stays pulsatile even under continuous CJC-1295 stimulation is part of why this behavior draws study. None of this is protocol advice; it is the biology behind a pattern people keep noticing.

CJC-1295 + Ipamorelin vs Sermorelin & Tesamorelin

Placing the stack next to the other GH peptides clears up where it fits. CJC-1295, Sermorelin, and Tesamorelin are all GHRH analogs, meaning they signal the pituitary to make growth hormone. Ipamorelin belongs to a different family, the GHRPs, which trigger the release pulse.

That is what makes the CJC-1295 + Ipamorelin pairing so popular: it puts one peptide from each family together, so both the production signal and the release trigger are covered. Sermorelin is the shorter, gentler GHRH analog, and Tesamorelin is the potent one with a visceral-fat approval, but neither is a GHRP, so neither pulls the release trigger the way Ipamorelin does.

There is a family resemblance worth naming here. Sermorelin, like the no-DAC CJC-1295, is a short GHRH fragment, so the two behave similarly and are sometimes discussed side by side. CJC-1295 with DAC extends that same GHRH signal across days, and Tesamorelin is the stabilized analog that earned a narrow visceral-fat approval. The GHRP, Ipamorelin, has no counterpart among the three, which is exactly why it gets added.

Choosing among these in a research setting depends on the question. A single GHRH analog studies the supply signal; the CJC + Ipamorelin blend studies the fuller, two-receptor pulse.

Composition, Ratio & Reconstitution

A standard blend arrives as a 1:1 ratio in a 10 mg vial, so 5 mg of CJC-1295 (usually the no-DAC form) and 5 mg of Ipamorelin, freeze-dried together as a white powder. The COA should confirm both peptides, their identity, and purity for the specific lot.

Reconstitution in research follows the usual lyophilized-peptide routine: bacteriostatic water or a sterile diluent added slowly against the vial wall, then gently swirling to dissolve the powder without shaking it. The volume of water chosen sets the concentration, which is a calculation researchers run per experiment. 

Once in solution, the blend is kept refrigerated and used within its stability window, since reconstituted peptides degrade faster than the dry powder. 

Dosage & Protocol in Research

The numbers below describe how the peptides appear in the research literature. They are reference points for laboratory work, and none of this is usage instruction.

In studies, CJC-1295 and Ipamorelin are given by subcutaneous injection, and the amounts are quoted in micrograms, often scaled to body weight in the formal trials. Research discussion of the blend tends to describe small, split doses timed around the body’s natural GH windows, such as before sleep, to stay in step with the pulsatile pattern the earlier sections described.

The timing logic traces back to the pulse. Because the pituitary releases its largest natural GH burst during deep sleep, research protocols often place a dose in that window to study how an added signal interacts with the body’s own peak. Splitting the total into a few smaller amounts across the day is the pattern that keeps the signal pulsatile, which connects back to the desensitization point above. One big injection would blur that on-off shape the pituitary responds to best.

For a research-use-only compound, there is no approved human protocol, and the figures in the literature exist to document how the peptides were tested. 

Downsides & Side Effects

The side-effect picture comes from research and self-report, and it belongs here as context only. This isn’t medical guidance. The most commonly noted issues track with a raised GH signal.

• Water retention and mild swelling, often in the hands, a classic sign of elevated GH.
• Injection-site reactions, such as redness or irritation where the subcutaneous dose lands.
• IGF-1 and insulin-sensitivity considerations, since a sustained GH signal can shift how the body handles glucose.
• Fading response over time, the desensitization pattern covered above, when signaling stays constant.

Is CJC-1295 + Ipamorelin Legal? FDA Status

Neither peptide is approved by the U.S. Food and Drug Administration for treatment or human use, and the blend has no approved medical indication. It reaches the market as a research-use-only chemical, sold and labeled for laboratory study.

That places it in the same category as most research peptides: legal to sell and buy for research when it is labeled and handled that way, and outside the approved-drug system entirely. Compounding-pharmacy access to these peptides has also tightened under recent regulatory attention. Rules in this area keep changing, and nothing here is legal advice.

Where to Source Research-Grade CJC-1295 + Ipamorelin

Sourcing quality rides on the documentation, and a blend adds one wrinkle: the COA has to verify both peptides in the vial. A few markers separate research-grade material from a guess.

• A third-party certificate of analysis for the exact lot, confirming both CJC-1295 and Ipamorelin.
• HPLC purity of 99% or higher, and a mass-spec reading that confirms each peptide is what the label says.
• Batch-level testing, so every lot carries its own fresh certificate.
• US-based operation with clear research-use-only labeling.

Among suppliers that meet these marks, Life Link Research publishes per-batch COAs and tests to high-purity standards before material ships, which is the verification this checklist is built around. Whatever the source, the vial should match a current, batch-specific certificate that names both peptides in the blend.

What Reddit & Experts Say

Track the peptide-research communities and video breakdowns from figures like Nick Norwitz and Dr. Jones, and the conversation keeps landing on a few practical points that go beyond the basic biology.

The most repeated correction is that the stack is not synthetic HGH. Newcomers often assume they are the same, and regulars keep pointing out that these peptides signal upstream through the pituitary, so the body still controls the release. That single clarification comes up in nearly every thread.

Close behind is the no-DAC preference and the desensitization talk. Experienced voices favor the short-acting Mod GRF 1-29 form for keeping the pulse clean, and they trade notes on why response fades when signaling runs constant, which loops back to cycling. 

The one point everyone agrees on, community and clinicians alike, is verification: post the COA, match the batch, and treat an unproven vial as an unknown before drawing any conclusion from it.

Frequently Asked Questions

What is CJC-1295 + Ipamorelin good for?

In research, the stack is studied for body composition, recovery and tissue repair, sleep quality, and IGF-1 activity. It gives labs a way to raise growth hormone and IGF-1 on demand and observe the downstream effects. These stay laboratory questions; human outcomes are a separate matter the evidence has yet to settle.

What are the benefits of taking them together?

The two peptides act on different receptors, so combining them produces a larger, more coordinated growth-hormone pulse than either alone. CJC-1295 builds the GH supply through the GHRH receptor, and Ipamorelin triggers the release through the ghrelin receptor. Because the receptors differ, the signals add up.

Does CJC-1295 + Ipamorelin affect testosterone?

Not directly, the stack acts on the growth-hormone axis, a separate system from the one that controls testosterone. It raises GH and IGF-1, and Ipamorelin’s selectivity keeps it clear of cortisol, prolactin, and ACTH. Any testosterone talk online is anecdote about indirect effects.

What are the downsides of CJC-1295?

Commonly noted points include water retention, injection-site reactions, IGF-1 and insulin-sensitivity considerations, and a fading response when signaling stays constant. It is not FDA-approved, it is research-use-only, and it is WADA-banned. A physician should answer any health question.

DAC vs No-DAC, which is used in the blend?

Usually No-DAC, the Mod GRF 1-29 form. It is short-acting and clears in minutes, which keeps it in step with Ipamorelin’s quick pulse. The DAC version lasts for days and produces a steadier signal, so it answers a different research question.

Is it the same as HGH?

No, synthetic HGH puts finished hormone into the bloodstream. CJC-1295 + Ipamorelin signals the pituitary upstream and lets the gland set the amount of GH released, which keeps the pattern closer to the body’s own pulse.

Summing Up

CJC-1295 + Ipamorelin pairs a GHRH analog with a selective GHRP so that one peptide builds the growth-hormone supply and the other releases it, producing a fuller pulsatile GH signal that the body converts to IGF-1. It usually comes as a 1:1 no-DAC 10 mg blend, and research studies it for body composition, recovery, and sleep. 

It works upstream through the pituitary, so it is not HGH, and it is not a guaranteed result. The compound is research-use-only, not FDA-approved, and WADA-prohibited. Check the Certificate of Analysis (COA) to make sure it lists both peptides before you buy anything.

Disclaimer

This article is for informational and research purposes only. The compounds described are research-use-only, not for human or veterinary consumption, and are not FDA-approved. Nothing here is medical advice, and no muscle, fat-loss, or other health outcome is claimed. Both peptides are prohibited by WADA. Consult a licensed physician with any health question. Intended for qualified researchers aged 18 and older.

Stay updated, free articles. Join our Telegram channel

Join